Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ZP7570 in healthy subjects
NCT03994549Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Jun 2019
- Primary completion
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in short bowel syndrome (SBS) comparing ZP7570 with Placebo (2 arms). Primary endpoint: Incidence of adverse events at 28 days. Started Jun 2019; status: completed.
02
Drugs
dapiglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03994549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994549.